1. eIF3b regulates the cell proliferation and apoptosis processes in chronic myelogenous leukemia cell lines via regulating the expression of C3G
- Author
-
Lai-Quan Huang, Jiawei Yan, Jun Huang, Xinyuan Zheng, Xiang-Xiang Chang, Lili Sheng, Jun Zhang, and Zhong-Ling Wei
- Subjects
0106 biological sciences ,0301 basic medicine ,Cell ,Apoptosis ,Bioengineering ,01 natural sciences ,Applied Microbiology and Biotechnology ,Flow cytometry ,Mice ,03 medical and health sciences ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,010608 biotechnology ,medicine ,Animals ,Humans ,Viability assay ,Eukaryotic Initiation Factors ,Guanine Nucleotide-Releasing Factor 2 ,Cell Proliferation ,medicine.diagnostic_test ,Chemistry ,Cell growth ,Intracellular Signaling Peptides and Proteins ,General Medicine ,Cell cycle ,medicine.disease ,030104 developmental biology ,medicine.anatomical_structure ,Cell culture ,Cancer research ,Heterografts ,K562 Cells ,Biotechnology ,Chronic myelogenous leukemia - Abstract
To investigate the functions of eIF3b in chronic myelogenous leukemia (CML). The expression of eIF3b was inhibited by transfecting aspecifically designed shRNA into the CML cell lines of TK-6 and K562. The CCK8 assay was conducted to determine cell viability, and flow cytometry was used to examine the change in the cell cycle and cell apoptosis. RNAsequencing was applied to screen the candidate targets of eIF3b to identify the underlying mechanisms of eIF3b.An in vivo tumour xenograft mouse model was established by injecting shRNA transfected cells into the NCG mice. The tumour size and body weight of mice were monitored every other day. The mice were sacrificed 2 weeks after the tumour cell injection. The expression of eIF3b and target genes in the tumour tissues were determined by immunohistochemical staining and Western blotting. The group with inhibited expression of eIF3b led to about 50% lower cell viability compared with that of the control group (P
- Published
- 2020
- Full Text
- View/download PDF